Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation

S. K. Metzelder; T. Schroeder; M. Lübbert; M. Ditschkowski; K. Götze; S. Scholl; R. G. Meyer; P. Dreger; N. Basara; M. F. Fey; H. R. Salih; A. Finck; T. Pabst; A. Giagounidis; G. Kobbe; E. Wollmer; J. Finke; A. Neubauer; A. Burchert

doi:10.1016/j.ejca.2017.09.016

Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation

S. K. Metzelder, T. Schroeder, M. Lübbert, M. Ditschkowski, K. Götze, S. Scholl, R. G. Meyer, P. Dreger, N. Basara, M. F. Fey, H. R. Salih, A. Finck, T. Pabst, A. Giagounidis, G. Kobbe, E. Wollmer, J. Finke, A. Neubauer, A. Burchert

Department of Internal Medicine III - Hematology and Medical Oncology

Research output: Contribution to journal › Article › peer-review

61 Scopus citations

Abstract

Background Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia (AML) relapsing after allogeneic stem cell transplantation (allo-SCT) has a dismal prognosis with limited therapeutic options. FLT3-ITD kinase inhibition is a reasonable but palliative experimental treatment alternative in this situation. Information on long-term outcome is not available. Methods We performed a long-term follow-up analysis of a previously reported cohort of 29 FLT3-ITD–positive AML patients, which were treated in relapse after allo-SCT with sorafenib monotherapy. Findings With a median follow-up of 7.5 years, 6 of 29 patients (21%) are still alive. Excluding one patient who received a second allo-SCT, five patients (17%) achieved sustained complete remissions with sorafenib. Four of these patients are in treatment-free remission for a median of 4.4 years. Interpretation Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD–positive AML relapsing after allo-SCT.

Original language	English
Pages (from-to)	233-239
Number of pages	7
Journal	European Journal of Cancer
Volume	86
DOIs	https://doi.org/10.1016/j.ejca.2017.09.016
State	Published - Nov 2017

Keywords

Acute myeloid leukemia
FLT3-ITD
Hematopoietic stem cell transplantation
Sorafenib

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2017.09.016

Cite this

Metzelder, S. K., Schroeder, T., Lübbert, M., Ditschkowski, M., Götze, K., Scholl, S., Meyer, R. G., Dreger, P., Basara, N., Fey, M. F., Salih, H. R., Finck, A., Pabst, T., Giagounidis, A., Kobbe, G., Wollmer, E., Finke, J., Neubauer, A., & Burchert, A. (2017). Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. European Journal of Cancer, 86, 233-239. https://doi.org/10.1016/j.ejca.2017.09.016

@article{8d5192dfda804ceb8ceed7e6db8ca732,

title = "Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation",

abstract = "Background Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia (AML) relapsing after allogeneic stem cell transplantation (allo-SCT) has a dismal prognosis with limited therapeutic options. FLT3-ITD kinase inhibition is a reasonable but palliative experimental treatment alternative in this situation. Information on long-term outcome is not available. Methods We performed a long-term follow-up analysis of a previously reported cohort of 29 FLT3-ITD–positive AML patients, which were treated in relapse after allo-SCT with sorafenib monotherapy. Findings With a median follow-up of 7.5 years, 6 of 29 patients (21%) are still alive. Excluding one patient who received a second allo-SCT, five patients (17%) achieved sustained complete remissions with sorafenib. Four of these patients are in treatment-free remission for a median of 4.4 years. Interpretation Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD–positive AML relapsing after allo-SCT.",

keywords = "Acute myeloid leukemia, FLT3-ITD, Hematopoietic stem cell transplantation, Sorafenib",

author = "Metzelder, {S. K.} and T. Schroeder and M. L{\"u}bbert and M. Ditschkowski and K. G{\"o}tze and S. Scholl and Meyer, {R. G.} and P. Dreger and N. Basara and Fey, {M. F.} and Salih, {H. R.} and A. Finck and T. Pabst and A. Giagounidis and G. Kobbe and E. Wollmer and J. Finke and A. Neubauer and A. Burchert",

note = "Publisher Copyright: {\textcopyright} 2017 Elsevier Ltd",

year = "2017",

month = nov,

doi = "10.1016/j.ejca.2017.09.016",

language = "English",

volume = "86",

pages = "233--239",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

Metzelder, SK, Schroeder, T, Lübbert, M, Ditschkowski, M, Götze, K, Scholl, S, Meyer, RG, Dreger, P, Basara, N, Fey, MF, Salih, HR, Finck, A, Pabst, T, Giagounidis, A, Kobbe, G, Wollmer, E, Finke, J, Neubauer, A & Burchert, A 2017, 'Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation', European Journal of Cancer, vol. 86, pp. 233-239. https://doi.org/10.1016/j.ejca.2017.09.016

TY - JOUR

T1 - Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation

AU - Metzelder, S. K.

AU - Schroeder, T.

AU - Lübbert, M.

AU - Ditschkowski, M.

AU - Götze, K.

AU - Scholl, S.

AU - Meyer, R. G.

AU - Dreger, P.

AU - Basara, N.

AU - Fey, M. F.

AU - Salih, H. R.

AU - Finck, A.

AU - Pabst, T.

AU - Giagounidis, A.

AU - Kobbe, G.

AU - Wollmer, E.

AU - Finke, J.

AU - Neubauer, A.

AU - Burchert, A.

PY - 2017/11

Y1 - 2017/11

N2 - Background Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia (AML) relapsing after allogeneic stem cell transplantation (allo-SCT) has a dismal prognosis with limited therapeutic options. FLT3-ITD kinase inhibition is a reasonable but palliative experimental treatment alternative in this situation. Information on long-term outcome is not available. Methods We performed a long-term follow-up analysis of a previously reported cohort of 29 FLT3-ITD–positive AML patients, which were treated in relapse after allo-SCT with sorafenib monotherapy. Findings With a median follow-up of 7.5 years, 6 of 29 patients (21%) are still alive. Excluding one patient who received a second allo-SCT, five patients (17%) achieved sustained complete remissions with sorafenib. Four of these patients are in treatment-free remission for a median of 4.4 years. Interpretation Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD–positive AML relapsing after allo-SCT.

AB - Background Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia (AML) relapsing after allogeneic stem cell transplantation (allo-SCT) has a dismal prognosis with limited therapeutic options. FLT3-ITD kinase inhibition is a reasonable but palliative experimental treatment alternative in this situation. Information on long-term outcome is not available. Methods We performed a long-term follow-up analysis of a previously reported cohort of 29 FLT3-ITD–positive AML patients, which were treated in relapse after allo-SCT with sorafenib monotherapy. Findings With a median follow-up of 7.5 years, 6 of 29 patients (21%) are still alive. Excluding one patient who received a second allo-SCT, five patients (17%) achieved sustained complete remissions with sorafenib. Four of these patients are in treatment-free remission for a median of 4.4 years. Interpretation Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD–positive AML relapsing after allo-SCT.

KW - Acute myeloid leukemia

KW - FLT3-ITD

KW - Hematopoietic stem cell transplantation

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85031720611&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2017.09.016

DO - 10.1016/j.ejca.2017.09.016

M3 - Article

C2 - 29055209

AN - SCOPUS:85031720611

SN - 0959-8049

VL - 86

SP - 233

EP - 239

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this